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Summary 
Multidrug resistance (MDR),  which is due, in part, to the overexpression of P-glycoprotein, 
confers resistance to a variety of natural product chemotherapeutic agents such as daunorubi- 
cin, vincristine,  and colchicine. RV  + cells  are a P-glycoprotein overexpressing variant of the 
HL60 myeloid leukemia cell line. In addition to classic MDR, IkV  + cells displayed relative re- 
sistance to complement-mediated cytotoxicity with both immunoglobulin G and M  antibodies 
against different cell surface antigens, but not to antibody-dependent cellular cytotoxicity and 
lymphokine-activated killing.  Complement  resistance  was  reversed both  by treatment  with 
verapamil and with specific monoclonal antibodies  (mAbs) capable of binding to P-glycopro- 
tein and blocking its function.  To further confirm that the resistance of IkV  + cells was not a 
consequence of the selection of the cells on vincristine, a second system involving P-glycopro- 
tein infectants was also  investigated.  K562  cells  infected with the  MDR1  gene,  which were 
never selected on chemotherapeutic drugs,  also  displayed relative resistance to complement- 
mediated cytotoxicity. This MDR1  infection-induced  resistance was  also  reversed by mAbs 
that bind to P-glycoprotein. Therefore, the MDI< phenotype as mediated by P-glycoprotein 
provides resistance to complement-mediated cytotoxicity. The increased intracellular pH and 
the decreased membrane potential due to the MDI< phenotype may result in abnormal mem- 
brane attack complex function. This observation may have implications for the possible mech- 
anisms of action  of P-glycoprotein and for a possible physiologic role for P-glycoprotein in 
protection against complement-mediated autolysis. 
M 
ultidrug resistance (MDP,.)  is characterized by broad 
resistance  to  several pharmacologically and  chemi- 
cally distinct  chemotherapeutic  compounds,  in  particular, 
the vinca alkaloids and the anthracyclines (1).  Tumor cells 
that are resistant to these compounds exhibit decreased re- 
tention of drugs over time (2). The MDk  phenotype (3) is 
the result of the overexpression of the mdrl gene product at 
least in part, a  170--180-kD glycoprotein known as P-gly- 
coprotein.  A  "drug pump"  model  has  been  proposed  in 
which  the  P-glycoprotein  serves  as  an  active  transporter 
that pumps drugs out of the cell (1, 3, 4). 
The cytotoxic abilities of mAbs M195  (anti-CD33)  (5) 
and M31  (anti-CD15) against HL60 myeloid leukemia cells 
and  a  MDt<  HL60  variant  that  overexpresses the  MDR 
protein  (RV +  [6]),  were examined.  In this paper,  we de- 
scribe the relative resistance of RV  + ceils to specific mAbs 
that react against cell surface protein  or carbohydrate tar- 
gets,  and  mediate  cytotoxicity  via  complement  fixation. 
MDP,.  reversal  studies  using  verapamil and  with  specific 
mAbs to P-glycoprotein showed that a significant portion 
of this newly described immunological resistance is medi- 
ated  by  P-glycoprotein  overexpression.  To  test  whether 
these  observations were not partly due to the selection of 
the tLV  + cells on vincristine or a spurious phenomenon for 
a  single  cell line,  K562  cells  and  MDR  K562/huMDR1 
infectants  (7),  which  were  never selected  on  drugs,  were 
analyzed in similar experiments. Taken together, the results 
are consistent with MDR  protein  overexpression mediat- 
ing resistance to complement mediated cytotoxicity. 
Materials and Methods 
Cells and Antibodies.  HL60 cells (acute myeloid leukemia, CD 15 +, 
and CD33+),  K562  cells (chronic  myeloid leukemia)  and K562 
clone 14 and K562 clone 18, both infected with the MDR1 gene 
(Mechetner,  E.B.,  unpublished  results), were maintained  at Me- 
morial  Sloan-Kettering  Cancer Center.  RV  + (a MDR-overex- 
pressing HL60 variant) was the generous gift of Dr. Melvin Cen- 
ter (Kansas State University, Manhattan,  KS) and was provided by 
Dr. Ellen Berman (Memorial Hospital). RV  + cells were grown in 
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dianapolis, IN) to maintain the MDR phenotype. 
M195 and HUM195 (anti-CD33) were prepared as described (5, 
8). HuG1 Fd79 (a human IgG2 control for HUM195)  (8),  was the 
generous gift of Man  Sung Co  (Protein Design Labs, Mountain 
View, CA). M31,  a murine anti-CD15 antibody was established 
at Memorial Sloan-Kettering Cancer  Center (Scheinberg,  D.A., 
unpublished  results).  T9  (anti-CD71)  was  purchased  from 
Coulter Corp.  (Hialeah,  FL).  HYB-241  was  a  generous  gift of 
Dr. James  O'Brien  (Memorial  Sloan-Kettering  Cancer  Center) 
who obtained the antibody from Dr. Lana Rittmann-Grauer (Hy- 
britech Inc.) (9). MRK-16, a IgG2a antibody, was purchased from 
Kamiya Biochemical Company (Thousand Oaks, CA), and UIC2, 
also an IgG2a antibody (10), was provided by Ingenex, Inc. 
Complement-mediated Cytotoxicity.  25 p,1 of cell suspension (106 
cells/ml) was incubated with 25  p,1 of diluted rabbit baby com- 
plement (Pel-Freeze Biologicals, Rogers, AK) and 25 p,1 of a se- 
rial dilution ofmAbs (M31, M195,  or T9) at 37~  and 5% CO  2. 
Cell kill was assayed using trypan blue at 30 or 60 min for M31 
and M195,  respectively. For cell kill using the T9 antibody,  the 
incubation times were 60 and 120 rain. Reversal of complement- 
mediated cytotoxicity by verapamil for RV  + cells was assayed as 
above  except that  from a  100-raM  stock solution  of verapamil, 
either a final concentration of 5-p,M or a 10-p,M solution ofver- 
apamil was added at the same time as the antibody. 
For the reversal of complement-mediated cytotoxicity by HYB- 
241 or UIC2 F(ab)' 2, cells were washed and resuspended to a con- 
centration of 106 cells/ml. UIC2 was cleaved with pepsin to yield 
electrophoretically pure F(ab)'2 fragments. HYB-241  antibody or 
UIC2 F(ab)'2 .was added at a final concentration of 20 p~g/ml to 
25  p,l  of cells.  HYB-241  antibody  was  incubated  with  cells at 
25~  for 60 rain, whereas UIC2 fragment was incubated with the 
cells at 4~  for 60-90 min. The remaining steps were the same as 
described above. 
Antibody-dependent  Cellular Cytotoxicity.  5-h chromium release 
assays were conducted as described (8) using PBMC from human 
volunteers as  effector cells and  HL60 and  RV  +  cells as positive 
targets. 
Daunorubicin  Resistance  and  Reversal  of Daunorubicin  Resistance 
with MRK- 16 or UIC2 Monoclonal Antibodies.  HL60  and  RV  + 
cells were washed and resuspended in complete RPMI media to a 
concentration of 5  X  105 cells/ml. 0.1 ml of cells and  0.1  ml of 
daunorubicin  (Chiron Therapeutics,  Emeryville, CA) were then 
added.  The mixture was incubated for 48 h  at 37~  in an atmo- 
sphere of 5% CO2. Cell kill was assayed  by trypan blue exclusion. 
For reversal, MRK-16 or UIC2 was added to the cells at a fi- 
nal concentration of 5 or 20 p~g/ml, respectively, and the mixture 
was incubated for 60 or 90 rain at 4~  Varied amounts of dauno- 
rubicin were then added. This mixture was then incubated for 24 
or 48 h at 37~  and 5% CO  z, before MTT (3-[4,5-dimethylthia- 
zol-2-yl]-2,5-dephenyltetrazolium bromide) assay. 
Results  and  Discussion 
We  confirmed  that  the  RV +  cells were  relatively resis- 
tant  to  daunorubicin  (EDs0  =  125  ng/ml  or 240  pM)  in 
comparison with HL60 cells (EDs0 -- 4  ng/ml or 8 pM).  In 
contrast,  RV +  cells were  more  sensitive to  cytosine arabi- 
noside  than  HL60  cells  (data  not  shown).  MDR  cells  in 
general do not exhibit cross-resistance  to cytosine arabino- 
side.  There was significant expression of P-glycoprotein on 
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Figure  1.  Relative resistance of MDR protein expressing RV  + cells 
(black) versus HL60 (open) to complement-mediated  cytotoxicity. (A) Re- 
sistance to M195  (an  IgG,  anti-CD33  antibody)  plus  complement.  (B) 
Resistance to M31  (an IgM, anti-CD15 antibody) plus complement.  Cell 
kill was assayed using trypan blue at 30 or 60 rain for M31 and M195, re- 
spectively. Controls included: no complement added (-C'); no antibody 
added  (-Ab).  When neither antibody  nor complement was added,  no 
killing was seen  (not  shown).  The data shown are a mean of duplicate 
measurements;  however,  the figure  is a representative  of eight experi- 
ments with similar results. (C~ Sensitivity ofRV  + cells to specific cell lysis 
by M195  ADCC. Percent specific lysis by M195  and human peripheral 
blood effectors (E) and HL60 (open) and RV  + (black) targets  (7)  deter- 
mined by chromium release assays. Assays were conducted in quadrupli- 
cate as described (14). Controls without antibody or effectors were nega- 
tive. 
the surface ofRV  + cells (mean peak fluorescence =  3.526) 
but not on HL60  (mean peak fluorescence =  0.315)  cells as 
shown  by  flow cytometry,  using indirect  irnmunofluores- 
cence with MRK-16,  an antibody specific for P-glycopro- 
tein  (11).  It was possible to partially reverse drug resistance 
to  daunorubicin  in this  HL60/RV  +  system by  use  of spe- 
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Figure 2.  Reversal of  resistance ofRV  + cells to complement-mediated 
cytotoxicity. (A) Reversal of resistance of RV  § cells to complement- 
mediated cytotoxicity  by addition of  verapamil to a final concentration of 
5- or 10-1~M solution, using HUM195 antibody. Verapamil alone at a fi- 
nal concentration of 10 p~M (+ VRP) had no cytotoxic effects. Controls 
without complement (-C') or without antibody (-Ab) were negative. 
(B) Reversal of  resistance ofRV  § cells to complement-mediated cytotox- 
icity using M31 antibody by addition of a 10-tzM solution of verapamil. 
Controls are as described in A. The data are a mean ofduphcate measure- 
ments and the figure is a representative of four experiments. (C) Reversal 
of resistance of RV  § cells to complement-mediated cytotoxicity  using the 
anti-P-glycoprotein mAb, UIC2.  UIC2 F(ab)'2 was added to 25 I~1 of 
cells at a final concentration of 20 I~g/ml, and was incubated with the 
cells at 4~  for 60 rain. The data shown are mean + standard deviation of 
experiments performed in quadruplicate. Samples that have no error bars 
have stardard deviations that are too small for representation on the graph. 
C is representative of three experiments. 
cific anti-P-glycoprotein antibodies, as previously described 
(10,  12). Both UIC2 and MRK-16 antibodies were able to 
reverse by "~  the daunorubicin resistance  exhibited by 
RV + cell at a wide range  (1-125  ng/ml)  of daunorubicin 
concentrations  (data not shown).  Thus,  the RV + cells dis- 
played a P-glycoprotein-mediated resistance to daunorubi- 
cin (12,  13). 
The levels of CD33 and CD15 target sites on HL60 and 
RV + were measured to insure that possible differences be- 
tween the cells were not simply an artifact of different anti- 
gen  density  of the  RV +  cells.  Quantitative  indirect  flow 
cytometry  (5)  showed  that  RV  +  cells  had  a  density  of 
CD15  and  CD33  antigen  expression  approximately  two- 
fold greater than the parental HL60 cells (data not shown). 
In the  presence  of complement,  M195  was  able  to kill 
the HL60 cells more potently and more effectively than the 
RV +  cells  over a  wide  range  of antibody  concentrations 
(Fig.  1 A).  M195  reacts with a protein antigen  (gp67)  ex- 
pressed at a density of about 10,000 sites per cell, and com- 
plement-mediated  killing  is  reduced  by internalization  of 
the antibody-antigen complex (5,  8).  RV + cells were also 
more resistant than HL60 cells to a wide range of effective 
concentrations of an IgM, M31, that recognizes the carbo- 
hydrate epitope Lewis X  (CD15) (Fig.  1 B). Therefore, the 
immunological  resistance  is  restricted  neither  to  protein 
targets nor to IgG-mediated cytotoxicity. 
In contrast, as had been shown previously (14), RV + cells 
were not resistant to antibody-dependent cellular cytotoxity 
(ADCC)  (Fig.  1  C)  or to LAK-mediated killing.  Interest- 
ingly, ADCC may work through two distinct mechanisms, 
perforin-mediated  lysis and  Fas-hgand-mediated  apoptosis 
(15).  The  dual  mechanism  of killing  could  contribute  to 
this lack of resistance. 
Complement-mediated cytotoxicity experiments were per- 
formed in the presence ofverapamil, a potent inhibitor of the 
ability of the P-glycoprotein to confer the MDR phenotype 
(16,  17). The addition ofverapamil to the complement cy- 
totoxicity assays  abrogated the resistance  of RV + cells  and 
resulted in more efficient killing  (Fig. 2, A  and B)  compa- 
rable to that for HL60 cells.  Reversal of the resistance phe- 
notype was obtained at several concentrations of verapamil 
ranging from 5 to 10 IxM. Controls performed with cells and 
verapamil without antibody or complement showed that the 
increased cytotoxicity was not due to verapamil itself which 
may be toxic over far longer periods (days, not minutes). 
P-glycoprotein-specific mAbs were used to confirm that 
the MDR  reversal observed with verapamil was the result 
of P-glycoprotein inhibition.  As described  above,  anti-P- 
glycoprotein antibodies,  UIC2 and MRK-16, can partially 
reverse  the  daunorubicin  resistance,  as  can  HYB-241  (9). 
Both UIC2 and MRK-16, but not HYB-241, direct com- 
plement-mediated cytotoxicity themselves on cells express- 
ing P-glycoprotein  (data  not shown);  therefore  an  F(ab)'2 
was  made  by pepsin  cleavage  of UIC2.  Both  the  UIC2 
F(ab)'2 (Fig. 2  C) and HYB-241 antibodies (not shown) re- 
versed the P-glycoprotein phenotype ofRV + cells in assays 
of complement-mediated cytotoxicity by M31. The rever- 
sal compares favorably to the reversal ofdaunorubicin cyto- 
toxicity.  This  reversal  effect was  seen  at  a  wide  range  of 
other concentrations of M31 ranging from a dilution of 1/12 
to  1/1,536  (data  not  shown).  Control  experiments  with 
UIC2  F(ab)'2 added  to HL60 plus  M31  and  complement 
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Figure 3.  Resistance and UIC2-mediated 
reversal of resistance of clone 14 and clone 
18 cells to daunorubicin and complement- 
mediated killing. Trypan blue exclusion was 
performed to determine cell viability at 48 h. 
(A)  K562  and clone  18  cells treated  with 
daunorubicin  and  UIC2.  K562  cells 
(squares);  clone  18  (circles);  clone  18  with 
UIC2 (triangles).  The data shown are mean 
values of experiments performed in quadru- 
plicate. Samples that have no error bars have 
standard deviations  that  are  too  small for 
representation  on  the  graph. UIC2  alone 
had no effect on cell viability for either cell 
line.  (B) Addition of T9 plus complement 
for 60 rain.  (C) Addition of T9 plus com- 
plement for  120 min. Cell kill was  deter- 
mined by trypan blue exclusion. No killing 
was seen in controls in which  no comple- 
ment was  added  (-C);  no  antibody  was 
added  (-Ab);  and  neither  antibody  nor 
complement was added. The data shown are 
a  mean  of  duplicate  measurements,  and 
therefore  standard deviation  is not shown. 
(D) Reversal of resistance to T9 plus com- 
plement for 120 rain with UIC2. U1C2 an- 
tibody was added to 25 I.zl of cells at a final 
concentration of 20 p.g/ml. UIC2 alone, or 
with T9 or complement, was not toxic. The 
data shown  are a mean of duplicate  mea- 
surements. 
did not increase complement-mediated cytotoxicity (data not 
shown), thus strengthening the relationship between P-gly- 
coprotein and complement resistance. Controls with UIC2 
and verapamil alone were not cytotoxic to the cells. 
To  confirm that  these  results were  not an isolated phe- 
nomenon  of the  HL60/RV +  system or a  consequence  of 
the  selection  of the  ILV  +  cells  on vincristine, K562  cells 
that were  infected with the MDP,  A  gene also were  exam- 
ined for resistance to daunorubicin and complement-medi- 
ated cytotoxicity. As determined by flow cytometry, clone 
14  and clone  18  cells,  like  RV +  cells,  had  significant ex- 
pression  of P-glycoprotein  on  their  surface,  whereas  the 
parental K562  cells had  none  (data not shown).  Clone  18 
cells  expressed  more  P-glycoprotein  than  clone  14  cells, 
characterized by densitometry of protein concentrations on 
a Western blot using anti-P-glycoprotein antibody and by 
flow cytometry (data not shown). 
Clone 14 and clone 18 cells were significantly resistant to 
daunorubicin cytotoxicity  (LDs0 of 125  and >125  ng/ml, 
respectively) as compared with the sensitive K562 cells (LDs0 
of 15  ng/ml).  Resistance was  directly related  to  P-glyco- 
protein expression as this resistance was  partially reversible 
with  the  addition  of the  mAb  UIC2  to  P-glycoprotein 
(Fig. 3 A). 
K562  cells do  not express  significant amounts of CD33 
or CD15. Therefore, an IgM mAb to CD71  (T9) was used 
instead. Quantitative flow cytometry for levels of CD71 on 
the K562  cells and the MDlk-positive clones showed  that 
the resistant clones have a  slightly higher density of CD71 
than  the  K562  cells  (data  not shown).  Clones  14  and  18 
were resistant to complement-mediated cytotoxicity (Fig. 3 
B).  The  resistance  of clone  14  to  complement-mediated 
cytotoxicity could be overcome by increasing the length of 
exposure  to  complement  from  60  to  120  min,  whereas 
clone  18  cells  remained  resistant  (Fig.  3  C).  Clone  18  is 
more resistant to daunorubicin than clone 14 and was more 
resistant to  complement-mediated cytotoxicity. The direct 
relationship between P-glycoprotein expression on the three 
K562 cell lines and both their drug and complement resis- 
tance  strengthens  the  association  between  P-glycoprotein 
function and resistance to complement-mediated cytotoxicity. 
UIC2  F(ab)'2 was  then used to  reverse the resistance of 
clone 18 to complement-mediated cytotoxicity. As was ob- 
served in the HL60/RV + system, UIC2 F(ab)' 2 was able to 
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the  sensitivity to  complement is  not  completely restored, 
the reversal does compare well to the reversal of daunom- 
bicin cytotoxicity (Fig. 3 A). UIC2 F(ab)'2 alone was found 
not to be cytotoxic to the cells. 
One  of the  assumptions of an immunological approach 
to the treatment of cancer is that cells  that are resistant to 
cytotoxic  drugs  because  of prior  exposure should  not  be 
cross-resistant to  immunotherapy.  Hence,  the  cross-resis- 
tance  observed  here  was  surprising.  Indeed,  ADCC  via 
specific antigen recognition was increased on 1LV  + cells,  as 
expected, as the R.V + cells express increased target antigen 
(14).  In addition  to  their sensitivity to ADCC,  the  RV  + 
cells were killed more effectively than the HL60 cells in cy- 
totoxicity experiments with cytosine arabinoside, a drug to 
which  MDR  tumor cells  do not develop cross-resistance. 
RV + cells  were also more sensitive to LAK cells,  another 
relatively nonspecific agent. 
The theory that  P-glycoprotein acts  as  an active efflux 
pump for drugs (18)  fails to explain the resistance to com- 
plement-mediated  cytotoxicity with  three  different  anti- 
bodies,  an IgG and two IgM.  If resistance to the comple- 
ment is mediated by MDR,  then a suitable explanation of 
its mechanism must take into account the effects of agents 
acting on the outside of the cell. 
By the use of verapamil and three,  different specific anti- 
bodies, we were able to confirm that P-glycoprotein itself 
was involved in the resistance to complement-mediated cy- 
totoxicity  in  two  different  systems.  The  observation  that 
UIC2 F(ab)'2 did not increase complement-mediated cyto- 
toxicity when in the presence of HL60 cells plus comple- 
ment, strongly reaffirms P-glycoprotein's involvement with 
complement resistance. In addition, both drug and comple- 
ment resistance in this system correlated directly with the 
levels of P-glycoprotein expression. However, because the 
RV + cells were derived by selection in vincristine, it is pos- 
sible that other mechanisms of drug resistance are present in 
these cells, but not in the K562 system. 
Other explanations for the broad resistance  observed might 
include altered binding of the antibodies to their target or a 
change  in  the  internalization  kinetics  of the  conjugates, 
yielding decreased residence time at the surface. The kinet- 
ics  of internalization  of M195  bound  to  RV  +  and HL60 
cells are similar, however (data not shown).  The increased 
sensitivity to ADCC argues against a significant decrease in 
antigen binding, since decreased binding would conversely 
reduce ADCC.  Thus, alterations in antigen binding or in- 
ternalization rates fail to provide a comprehensive explana- 
tion for the resistance we observe. 
Significant changes in plasma membrane electrochemical 
potential have been observed in MDR  cells  (19)  and these 
appear to  be  due  to  P-glycoprotein  (20).  These  changes 
typically include  elevated intracellular pH  (pHi), which  is 
also referred to as increased ApH, as well as decreased (less 
negative) electrical membrane potential (A~). These changes 
likely have broad effects on many events that occur at the 
cell surface. Compared with HL60 cells,  R.V  + cells have a 
significant elevated pHi as well as a decreased A~  (Weis- 
burg, J.H., D.A. Scheinberg, and P.D. Roepe, unpublished 
results);  thus, it is possible that these changes contribute to 
the resistance we measured. Indeed the pore-forming pro- 
tein from Trypanosoma cruzi, which is immunologically re- 
lated to human C9 protein (the ninth component of com- 
plement) forms "pores" (or "complement channels") readily 
at lower pH but very inefficiently at higher pH (21).  In ad- 
dition, Jackson et al.  (22)  have reported rather significant 
decreases  in  mean  complement  channel  conductance,  as 
well as altered efficiency of channel formation, for muscle 
cell membranes clamped to -47 versus -60 inV. 
The relationship between the MDR phenotype and com- 
plement  resistance  raises  questions  about  the  physiologic 
role of P-glycoprotein in protection against autolysis. Inter- 
estingly,  CD34-positive  hematopoietic  stem  cells  express 
P-glycoprotein (23) as do many normal human tissues  (24). 
IL-2  transport may also  be  modulated  by P-glyr 
(25).  It is hypothesized that the function of P-glycoprotein 
is to protect against cytotoxic plant alkaloids and other di- 
etary xenobiotic substances  (24).  Many of the  sites  where 
P-glycoprotein is found normally in the body are also sites 
of bacterial entry and inflammation.  It could be hypothe- 
sized that P-glycoprotein may have evolved to protect the 
body against endogenous toxins,  such as complement, in- 
stead  of,  or  in  addition  to,  exogenous  substances.  Addi- 
tional work to  elucidate  the  mechanism of resistance  and 
kinetics of pore formation in the MDR cells is in progress. 
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